Drug Pricing & Pharmacy

CMS drug-pricing activity under the Trump administration is shifting from broad inflation-era price controls toward implementation details that will directly affect MA, Part D, Medicaid, and VBC contracting economics—especially as MA plans prepare for Part B negotiated drug prices and rebate/NAMBA-driven Part D bid recalibration. The strategic tension is intensifying between federal pharmacy demonstrations and pricing models meant to curb spending, and manufacturers—particularly midsize biotechs—arguing that CMS pricing rules could suppress investment and limit access, creating new pressure on payers and providers to use outcomes-based contracts as a bridge between affordability and innovation. For ACOs, MAOs, and Medicaid programs, the practical implication is that pharmacy risk is becoming more embedded in total-cost-of-care performance, requiring tighter formulary strategy, specialty drug management, and data infrastructure to link drug spend to outcomes (Avalere on Part B negotiated prices; CHCS on federal pharmacy demonstrations.